Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REperfusion with P2Y12 inhibitors (cangrelor) in addition to mechanical thrombectomy for perfusion-imaging-selected acute ischemic stroke
2020-005451-20Phase 3Active
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Apr 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cangrelor in acute ischemic stroke (AIS) (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Favorable functional outcome at 3 months. Started Apr 2021; status: active.
02
Drugs
cangrelor
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on 2020-005451-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005451-20.